Literature DB >> 18325297

Update on the therapy of the trigeminal autonomic cephalalgias.

Marc E Lenaerts1.   

Abstract

The treatment of trigeminal autonomic cephalalgias requires very careful attention to clinical aspects. It is important to spend enough time assessing the patient to arrive at an accurate diagnosis. Identifying trigger factors (eg, alcohol), when applicable, is part of the therapy, as behavior modifications may be necessary. Cluster headache treatment should never be delayed; patients should be able to visit the clinic within 48 hours to expedite medication initiation. Abortive therapy typically is best achieved with nasal oxygen, sumatriptan injections, or both. Typically, a steroid taper is begun and will be continued for a few days. A prophylactic agent such as verapamil or topiramate also is initiated immediately and will be taken for a period slightly beyond the expected duration of the last cluster period before an attempt is made to taper it off. For chronic cluster headache, lithium carbonate is recommended after a few weeks if these other treatments have failed. If more than three regimens of medical therapy fail, patients should be considered for neurostimulation procedures. Paroxysmal hemicrania most often responds to indomethacin. Failure may be due to a dosage that is too low. Gastric protection should always be given, because this medication has a high rate of gastric complications. Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) remain very difficult to treat. Lamotrigine is the first recommendation. Overall, one of the most crucial aspects of the management of patients with these disabling headache syndromes is patient education regarding what their disorder is and the reasoning behind the therapeutic options offered.

Entities:  

Year:  2008        PMID: 18325297     DOI: 10.1007/s11940-008-0004-2

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  43 in total

1.  SUNCT syndrome responsive to lamotrigine.

Authors:  Jose M Gutierrez-Garcia
Journal:  Headache       Date:  2002-09       Impact factor: 5.887

2.  Stimulation of the superior sagittal sinus increases metabolic activity and blood flow in certain regions of the brainstem and upper cervical spinal cord of the cat.

Authors:  P J Goadsby; A S Zagami
Journal:  Brain       Date:  1991-04       Impact factor: 13.501

3.  Response of cluster headache to psilocybin and LSD.

Authors:  R Andrew Sewell; John H Halpern; Harrison G Pope
Journal:  Neurology       Date:  2006-06-27       Impact factor: 9.910

4.  Treatment of acute cluster headache with sumatriptan.

Authors: 
Journal:  N Engl J Med       Date:  1991-08-01       Impact factor: 91.245

5.  Gamma knife treatment for refractory cluster headache: prospective open trial.

Authors:  A Donnet; D Valade; J Régis
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-02       Impact factor: 10.154

6.  Parenteral indomethacin (the INDOTEST) in cluster headache.

Authors:  F Antonaci; A Costa; S Ghirmai; G Sances; O Sjaastad; G Nappi
Journal:  Cephalalgia       Date:  2003-04       Impact factor: 6.292

7.  Cyberknife targeting the pterygopalatine ganglion for the treatment of chronic cluster headaches.

Authors:  Shivanand P Lad; John D Lipani; Iris C Gibbs; Steven D Chang; John R Adler; Jaimie M Henderson
Journal:  Neurosurgery       Date:  2007-03       Impact factor: 4.654

Review 8.  Medication overuse headache.

Authors:  M E Lenaerts; J R Couch
Journal:  Minerva Med       Date:  2007-06       Impact factor: 4.806

9.  Sumatriptan in chronic cluster headache: results of continuous treatment for eleven months.

Authors:  K Ekbom; E Waldenlind; J Cole; A Pilgrim; A Kirkham
Journal:  Cephalalgia       Date:  1992-08       Impact factor: 6.292

Review 10.  Acute pharmacotherapy of migraine, tension-type headache, and cluster headache.

Authors:  Peer Tfelt-Hansen
Journal:  J Headache Pain       Date:  2007-05-11       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.